As we continue to gauge the financial impact of the coronavirus, we found this statement from Lilly very interesting – per a press release issued yesterday;
“Among the concerns raised due to the impact of the novel coronavirus is whether patients can count on a reliable supply of medicine. Lilly does not anticipate shortages for any of our products, including all forms of insulin.
Since the initial outbreak, Lilly has been closely monitoring our supply chain for potential impact to the supply of our medicines around the world. Lilly does not source active pharmaceutical ingredients (API) for any of our approved . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.